Physician profile
Ari Daniels
NPI 1497421853
$3,227.86
in general payments reported to CMS, 2019-2025
20 companies · $285 in 2025
The $285 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,431 · 2023: $971 · 2024: $540 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,796.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $766.57 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $528.73 | 2022-2025 | Caplyta |
| Alkermes, INC. | $364.30 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $208.21 | 2022-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $173.90 | 2022-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $168.98 | 2022-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $162.57 | 2022-2024 | Rexulti |
| Corium, LLC | $140.52 | 2022-2024 | Azstarys, Azstarys |
| Almatica Pharma LLC | $130.07 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Sunovion Pharmaceuticals INC. | $124.53 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $102.02 | 2022-2024 | Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $91.04 | 2023-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $66.07 | 2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $58.80 | 2022-2023 | Quviviq |
| Noven Therapeutics, LLC | $55.97 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Owp Pharmaceuticals, INC. | $26.53 | 2022-2023 | Lamotrigine, Subvenite |
| Janssen Pharmaceuticals, INC | $16.66 | 2024 | Invega |
| Bausch Health US, LLC | $15.38 | 2022 | |
| Tris Pharma INC | $13.72 | 2024 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $13.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ari Daniels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.